Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Scinai Immunotherapeutics ( (SCNI) ).
On September 18, 2025, Scinai Immunotherapeutics was informed that its grant application for Euro 12 million under the European Funds for a Modern Economy program in Poland was not selected for funding. The application was intended to support the development of PC111, a monoclonal antibody licensed from Pincell srl. Scinai plans to appeal the decision, believing that certain project aspects were misanalyzed, with a final determination expected by the end of 2025. The outcome of this appeal could significantly impact Scinai’s development plans and market positioning.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates in the biotechnology industry, focusing on the development of monoclonal antibodies for treating autoimmune and severe skin conditions such as pemphigus vulgaris, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. The company is actively engaged in expanding its market presence through strategic acquisitions and collaborations, particularly in Europe.
Average Trading Volume: 1,096,697
Technical Sentiment Signal: Sell
Current Market Cap: $1.34M
Find detailed analytics on SCNI stock on TipRanks’ Stock Analysis page.